Paper Details

  1. Home
  2. Paper Details

Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.

Author: CarloniFederica, CastellaniCinzia, DrudiFabrizio, Lazzari-AgliLuigi, SartoriSergio, ScarpiEmanuela, TassinariDavide, TombesiPaola

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Novel second-line treatments for nonsmall cell lung cancer (NSCLC), including pemetrexed, oral topotecan, and gefitinib, were noninferior to every-3-weeks docetaxel in terms of one-year survival rate. However, these treatments showed a significant advantage in quality of life and safety, highlighting their palliative value in NSCLC.
Paper Details　
Original Abstract of the Article :
BACKGROUND: To assess the role of the novel second-line treatments in nonsmall cell lung cancer (NSCLC). METHODS: A systematic review of the literature with meta-analysis of phase III randomized clinical trials (RCTs) was independently performed by 3 authors. All the trials comparing any novel trea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/COC.0b013e31822dfd13

データ提供：米国国立医学図書館（NLM）

Second-Line Treatments for Non-Small Cell Lung Cancer: A Non-Inferiority Analysis

This research dives into the desert of second-line treatments for non-small cell lung cancer (NSCLC). The authors conducted a systematic review and meta-analysis of phase III randomized clinical trials (RCTs) to assess the effectiveness of novel treatments. The goal was to see if these new therapies were 'non-inferior' to the standard treatment, docetaxel, given every three weeks. They looked at the one-year survival rate as the primary outcome and quality of life and safety as secondary outcomes.

Pemetrexed, Oral Topotecan, and Gefitinib: Non-Inferior but Not Superior

The results of this meta-analysis showed that pemetrexed, oral topotecan, and gefitinib were all non-inferior to docetaxel in terms of one-year survival. However, the improvement in overall survival was modest, like a camel finding a tiny oasis in a vast desert. But the real gems were the improvements in quality of life and safety for patients receiving the experimental treatments. These new therapies provided a welcome respite for patients with NSCLC, offering better quality of life and reduced side effects.

The Importance of Quality of Life and Safety

The authors highlighted the importance of quality of life and safety, even if there wasn’t a significant improvement in overall survival. It's like finding a cool breeze in the desert – it might not change the landscape dramatically, but it makes the journey much more bearable. This study underscores that even small improvements in quality of life can significantly benefit patients undergoing cancer treatment, making a huge difference in their daily lives.

Dr. Camel's Conclusion

This study, like a map leading to a hidden oasis, provided valuable insight into the effectiveness of second-line therapies for NSCLC. Although the experimental treatments did not offer a dramatic increase in survival, they showed a clear improvement in quality of life and safety. This research underscores the importance of considering patient well-being and the potential of palliative care in improving the experience of patients with cancer.
Date :
  1. Date Completed 2013-01-28
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

21926899

DOI: Digital Object Identifier

10.1097/COC.0b013e31822dfd13

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.